Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Neos Therapeutics (NEOS)

Neos Therapeutics (NEOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,221
  • Shares Outstanding, K 49,757
  • Annual Sales, $ 64,650 K
  • Annual Income, $ -16,900 K
  • 60-Month Beta 1.45
  • Price/Sales 1.00
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NEOS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.44
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/26/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview

Details
  • Implied Volatility 0.00%
  • Historical Volatility 94.39%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +1,427,242.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6700 +71.64%
on 03/05/21
1.6800 -31.55%
on 03/18/21
+0.1400 (+13.86%)
since 02/19/21
3-Month
0.6100 +88.52%
on 01/04/21
1.6800 -31.55%
on 03/18/21
+0.4799 (+71.62%)
since 12/18/20
52-Week
0.4501 +155.50%
on 10/01/20
1.6800 -31.55%
on 03/18/21
+0.4000 (+53.33%)
since 03/19/20

Most Recent Stories

More News
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma

Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics

NEOS : 1.1500 (-2.54%)
AYTU : 6.55 (-1.36%)
Aytu BioScience Announces Close of Merger with Neos Therapeutics

$100M revenue specialty pharmaceutical company on an accelerated path to profitability[1] Company name change to Aytu BioPharma, Inc. becomes effective today Former Neos Therapeutics board members Beth...

NEOS : 1.1500 (-2.54%)
AYTU : 6.55 (-1.36%)
Thinking about buying stock in Neos Therapeutics, Oriental Culture, Sino-Global Shipping, Bank of America, or Can Fite Biopharma?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, OCG, SINO, BAC, and CANF.

CANF : 2.09 (-4.13%)
NEOS : 1.1500 (-2.54%)
OCG : 5.67 (-4.87%)
SINO : 4.75 (-1.66%)
BAC : 39.24 (+1.29%)
Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

Patrick Heron to leave the Board

ITRM : 1.0100 (-3.81%)
XERS : 3.84 (-0.52%)
NEOS : 1.1500 (-2.54%)
Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote "FOR" the Pending Merger With Aytu BioScience

- The Neos Therapeutics Board of Directors recommend stockholders vote "FOR" the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time -

NEOS : 1.1500 (-2.54%)
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote "FOR" the Pending Merger With Aytu BioScience

- The Neos Therapeutics Board of Directors recommend stockholders vote "FOR" the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time -

NEOS : 1.1500 (-2.54%)
Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial Results

--Q4 2020 Net Investment Income Provides 116% Coverage of Base Distribution Payout

DASH : 149.92 (-1.04%)
MASS : 50.92 (-3.36%)
ACEV : 9.92 (+0.20%)
ASPL : 10.05 (unch)
ACTC : 15.70 (-1.32%)
PACE : 9.96 (-0.40%)
UBER : 60.11 (-1.04%)
UROV : 16.24 (+0.06%)
NEOS : 1.1500 (-2.54%)
AYTU : 6.55 (-1.36%)
HTGC : 16.95 (+0.30%)
HCXZ : 25.28 (+0.09%)
HCXY : 26.83 (+0.30%)
Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year

NEOS : 1.1500 (-2.54%)
AYTU : 6.55 (-1.36%)
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021

- Record date for each Special Meeting of Stockholders is February 5, 2021 -

AYTU : 6.55 (-1.36%)
NEOS : 1.1500 (-2.54%)
Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm - CPAH, UROV, ANH, CGIX, CBLI, NEOS

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

CPAH : 3.48 (+0.58%)
UROV : 16.24 (+0.06%)
ANH : 2.98 (+0.34%)
CGIX : 4.61 (-2.33%)
CBLI : 5.43 (-9.20%)
NEOS : 1.1500 (-2.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD;...

See More

Key Turning Points

3rd Resistance Point 1.3182
2nd Resistance Point 1.2485
1st Resistance Point 1.1993
Last Price 1.1500
1st Support Level 1.0804
2nd Support Level 1.0107
3rd Support Level 0.9615

See More

52-Week High 1.6800
Fibonacci 61.8% 1.2102
Last Price 1.1500
Fibonacci 50% 1.0651
Fibonacci 38.2% 0.9199
52-Week Low 0.4501

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar